Shah DK - Search Results

1

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. Leal M, et al. Among authors: shah dk. Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499. Ann N Y Acad Sci. 2014. PMID: 25123209 Review.

2

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.

Shah DK, Haddish-Berhane N, Betts A. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):643-59. doi: 10.1007/s10928-012-9276-y. Epub 2012 Nov 15. J Pharmacokinet Pharmacodyn. 2012. PMID: 23151991

3

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. Haddish-Berhane N, et al. Among authors: shah dk. J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10. J Pharmacokinet Pharmacodyn. 2013. PMID: 23933716

4

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

Klinguer-Hamour C, Strop P, Shah DK, Ducry L, Xu A, Beck A. Klinguer-Hamour C, et al. Among authors: shah dk. MAbs. 2014 Jan-Feb;6(1):18-29. doi: 10.4161/mabs.27437. MAbs. 2014. PMID: 24423618 Free PMC article.

5

A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.

Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, Haddish-Berhane N, Betts A, Leal M. Shah DK, et al. AAPS J. 2014 May;16(3):452-63. doi: 10.1208/s12248-014-9576-9. Epub 2014 Mar 1. AAPS J. 2014. PMID: 24578215 Free PMC article.

6

Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).

Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. Singh AP, et al. Among authors: shah dk. AAPS J. 2016 Jul;18(4):861-75. doi: 10.1208/s12248-016-9904-3. Epub 2016 Mar 30. AAPS J. 2016. PMID: 27029797 Free PMC article.

7

Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).

Singh AP, Shah DK. Singh AP, et al. Among authors: shah dk. AAPS J. 2017 Jul;19(4):1054-1070. doi: 10.1208/s12248-017-0071-y. Epub 2017 Apr 3. AAPS J. 2017. PMID: 28374319 Free PMC article.

8

Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.

Khot A, Tibbitts J, Rock D, Shah DK. Khot A, et al. Among authors: shah dk. AAPS J. 2017 Nov;19(6):1715-1734. doi: 10.1208/s12248-017-0131-3. Epub 2017 Aug 14. AAPS J. 2017. PMID: 28808917 Free PMC article.

9

Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.

Shah DK, Loganzo F, Haddish-Berhane N, Musto S, Wald HS, Barletta F, Lucas J, Clark T, Hansel S, Betts A. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):339-349. doi: 10.1007/s10928-018-9577-x. Epub 2018 Feb 8. J Pharmacokinet Pharmacodyn. 2018. PMID: 29423862

10

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART^®.

Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, Clark T, Kamperschroer C, Root A, Hooper A, Chen X. Betts A, et al. Among authors: shah dk. AAPS J. 2019 May 22;21(4):66. doi: 10.1208/s12248-019-0332-z. AAPS J. 2019. PMID: 31119428 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters